For patients with recurrent or metastatic (R/M) cervical cancer (squamous cell carcinoma, adenocarcinoma, or adenosquamous subtypes) with a PD-L1-positive status, current guidelines suggest prioritized treatment approaches for initial therapy as follows: 1) pembrolizumab combined with cisplatin/carboplatin and paclitaxel, optionally combined with bevacizumab; 2) cisplatin/carboplatin administered alongside paclitaxel and bevacizumab; and 3) atezolizumab in conjunction with cisplatin/carboplatin, paclitaxel, and bevacizumab. This evidence concerns the gene CD274 and cervical carcinoma.